Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$34.10+0.41%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AMLX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -21.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
AMLX — debt issuance
Dated 2026-08-20
Entry into a Material Definitive Agreement. On August 19, 2026, Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale of an aggregate of 14,090,000 shares (the “Firm Shares”) of the Company’s common st…
Why it matters: Submitting the NDA is crucial for avexitide's path to market. Approval could address a significant unmet need in PBH treatment.
Supportive ifManagement says they plan to submit the NDA for avexitide by the end of 2026.
Worry ifThe NDA submission is delayed past 2026. This shows possible issues with readiness.
Why it matters: Higher SG&A expenses show investment in getting avexitide ready for the market. Changes may mean new strategies.
Watch forSG&A expenses rise, showing ongoing investment in commercial work.
Also watch forSG&A expenses fall, suggesting a slowdown in getting ready for the market.
Why it matters: The earnings report will show if revenue trends are improving or worsening. This is key for understanding the company's future.
Watch forEarnings report shows revenue growth above 5% year over year.
Also watch forEarnings report shows revenue decline year over year.
Why it matters: Progress on AMX0318 could open new markets for Amylyx. Delays could hurt growth prospects.
Supportive ifThey announced big progress or new partnerships for AMX0318 to treat rare diseases.
Worry ifThey announced delays or problems in developing AMX0318.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$255 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $561 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,061 loss on $10,000 · 30.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Progress on AMX0318 is important for Amylyx's growth in rare diseases. It shows their innovation capability.
Supportive ifThere are big milestones in AMX0318 development.
Worry ifNo news or problems reported in AMX0318 development.
Why it matters: The IND filing for AMX0318 is a key step for developing new treatments. Delays could slow progress.
Supportive ifManagement announces the IND filing for AMX0318 is on track for 2027.
Worry ifManagement delays the IND filing beyond 2027.
Why it matters: Having enough cash until 2028 is important for operations and growth.
Watch forCash and equivalents stay stable or grow. This confirms the runway into 2028.
Also watch forCash drops a lot. This shows possible funding issues for ongoing projects.
Why it matters: The health care sector is slowing. If growth re-accelerates, it could help Amylyx's outlook.
Supportive ifHealth care sector revenue growth is speeding up again. It is close to 10% year over year.
Worry ifHealth care sector revenue growth continues to decelerate below 5% year over year.
Why it matters: This data will help us understand how well AMX0114 works for ALS. Good results could help further development.
Supportive ifThe presentation shows early positive changes in ALS patients who take AMX0114.
Worry ifThe presentation shows no major changes in ALS biomarkers.
Why it matters: This trial's completion is key for the company's future product pipeline and cash flow.
Supportive ifThe trial is done and the results are good.
Worry ifThe trial is delayed or the results are bad.